Morgan Stanley’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-515,099
| Closed | -$7.7M | – | 8021 |
|
|
2022
Q4 | $7.7M | Buy |
515,099
+409,624
| +388% | +$5.67M | ﹤0.01% | 3330 |
|
|
2022
Q3 | $869K | Buy |
105,475
+59,432
| +129% | +$456K | ﹤0.01% | 4959 |
|
|
2022
Q2 | $302K | Buy |
46,043
+1,903
| +4% | +$9.22K | ﹤0.01% | 5685 |
|
|
2022
Q1 | $246K | Buy |
44,140
+12,052
| +38% | +$49.7K | ﹤0.01% | 5803 |
|
|
2021
Q4 | $151K | Sell |
32,088
-39,828
| -55% | -$247K | ﹤0.01% | 6212 |
|
|
2021
Q3 | $445K | Buy |
71,916
+61
| +0.1% | +$365 | ﹤0.01% | 5567 |
|
|
2021
Q2 | $474K | Sell |
71,855
-76,177
| -51% | -$525K | ﹤0.01% | 5558 |
|
|
2021
Q1 | $1.08M | Buy |
148,032
+127,766
| +630% | +$1.1M | ﹤0.01% | 4678 |
|
|
2020
Q4 | $117K | Buy |
20,266
+2,647
| +15% | +$15.2K | ﹤0.01% | 5849 |
|
|
2020
Q3 | $105K | Sell |
17,619
-226,792
| -93% | -$1.12M | ﹤0.01% | 5414 |
|
|
2020
Q2 | $1.26M | Buy |
244,411
+232,403
| +1,935% | +$1.47M | ﹤0.01% | 3988 |
|
|
2020
Q1 | $43K | Sell |
12,008
-6,758
| -36% | -$33.5K | ﹤0.01% | 5529 |
|
|
2019
Q4 | $118K | Sell |
18,766
-3,390
| -15% | -$25K | ﹤0.01% | 5602 |
|
|
2019
Q3 | $187K | Sell |
22,156
-17,818
| -45% | -$133K | ﹤0.01% | 5165 |
|
|
2019
Q2 | $269K | Buy |
39,974
+29,035
| +265% | +$249K | ﹤0.01% | 4892 |
|
|
2019
Q1 | $89K | Sell |
10,939
-16,965
| -61% | -$175K | ﹤0.01% | 5441 |
|
|
2018
Q4 | $446K | Buy |
27,904
+448
| +2% | +$9.86K | ﹤0.01% | 4856 |
|
|
2018
Q3 | $909K | Sell |
27,456
-3,647
| -12% | -$93.7K | ﹤0.01% | 4615 |
|
|
2018
Q2 | $703K | Buy |
31,103
+11,854
| +62% | +$281K | ﹤0.01% | 4863 |
|
|
2018
Q1 | $558K | Buy |
19,249
+5,356
| +39% | +$157K | ﹤0.01% | 4942 |
|
|
2017
Q4 | $388K | Buy |
13,893
+7,786
| +127% | +$242K | ﹤0.01% | 5109 |
|
|
2017
Q3 | $223K | Buy |
6,107
+3,678
| +151% | +$114K | ﹤0.01% | 5306 |
|
|
2017
Q2 | $54K | Buy |
2,429
+2,379
| +4,758% | +$18.7K | ﹤0.01% | 5835 |
|
|
2017
Q1 | $0 | Hold |
50
| – | – | ﹤0.01% | 6658 |
|
|
2016
Q4 | $0 | Sell |
50
-9
| -15% | -$60 | ﹤0.01% | 6607 |
|
|
2016
Q3 | $0 | Sell |
59
-50
| -46% | -$471 | ﹤0.01% | 6606 |
|
|
2016
Q2 | $1K | Sell |
109
-1,536
| -93% | -$14.8K | ﹤0.01% | 6464 |
|
|
2016
Q1 | $15K | Sell |
1,645
-3,961
| -71% | -$39.2K | ﹤0.01% | 6026 |
|
|
2015
Q4 | $70K | Sell |
5,606
-4,024
| -42% | -$47.8K | ﹤0.01% | 5589 |
|
|
2015
Q3 | $116K | Sell |
9,630
-10,001
| -51% | -$145K | ﹤0.01% | 5358 |
|
|
2015
Q2 | $342K | Buy |
19,631
+14,602
| +290% | +$263K | ﹤0.01% | 4954 |
|
|
2015
Q1 | $72K | Buy |
5,029
+3,789
| +306% | +$41.4K | ﹤0.01% | 5662 |
|
|
2014
Q4 | $11K | Sell |
1,240
-198
| -14% | -$1.81K | ﹤0.01% | 6201 |
|
|
2014
Q3 | $16K | Sell |
1,438
-3,039
| -68% | -$38.6K | ﹤0.01% | 6084 |
|
|
2014
Q2 | $82K | Buy |
4,477
+2,206
| +97% | +$28.7K | ﹤0.01% | 5583 |
|
|
2014
Q1 | $34K | Sell |
2,271
-12,286
| -84% | -$221K | ﹤0.01% | 5838 |
|
|
2013
Q4 | $267K | Sell |
14,557
-2,463
| -14% | -$49.3K | ﹤0.01% | 4884 |
|
|
2013
Q3 | $351K | Sell |
17,020
-23,599
| -58% | -$540K | ﹤0.01% | 4573 |
|
|
2013
Q2 | $1.02M | Buy |
+40,619
| New | +$1.74M | ﹤0.01% | 3717 |
|
Morgan Stanley's AVEO Position: Q1 2023 in Review
Morgan Stanley sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 515,099 shares — an estimated $7.7M sold.
Morgan Stanley first reported a position in AVEO in Q2 2013 and held it in 39 quarters. The position peaked at $7.7M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Morgan Stanley reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Morgan Stanley sold 515,099 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $7.7M.
- Morgan Stanley first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 39 quarters.
- Morgan Stanley's AVEO Pharmaceuticals, Inc. position peaked at $7.7M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.